GenFleet Therapeutics
http://www.genfleet.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenFleet Therapeutics
Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
2021 Marked New Era Of Domestic Collaboration in China
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice